In This Section

Contact
E-mail
liy3 [at] email.chop.edu
Phone
Location - People View
Room 4032

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Research Topics
Yimei Li, PhD
Yimei Li
Research Biostatistician

Dr. Li's methodology research interests include survival analysis, longitudinal data analysis, Bayesian methods, and clinical trial design. Her current research involves statistical designs and analysis for early phase cancer clinical trials and cancer trials with multiple survival endpoints.

AddtoAny
Share:

Bio

Dr. Li's methodology research interests include survival analysis, longitudinal data analysis, Bayesian methods, and clinical trial design. Her current research involves statistical designs and analysis for early phase cancer clinical trials and cancer trials with multiple survival endpoints.

Her collaborative research focuses on pediatric oncology, including translational and clinical trials, cancer epidemiology, and behavioral and psychosocial intervention studies. She has extensive experience in the design, conduct, and analysis of various cancer studies, and has published more than 110 articles in the literatures of statistical methodology, cancer research, and other areas of medicine. She is also on the editorial board of the Journal of the National Cancer Institute.

Education and Training

BS, Peking University (Applied Mathematics), 2006

MS, University of Pennsylvania (Biostatistics), 2008

PhD, University of Pennsylvania (Biostatistics), 2010

Titles and Academic Titles

Research Biostatistician

Assistant Professor of Pediatrics

Assistant Professor of Biostatistics

Professional Memberships

American Statistical Association, 2007-

International Biometric Society, 2007-

International Chinese Statistical Association, 2011-

Publication Highlights

Pubmed:
Li Y, Wang M, Cheung K. Treatment and dose prioritization in early phase platform trials of targeted cancer therapies. J Royal Statistical Society: Series C (Applied Statistics). 2018 Jan; doi: 10.1111/rssc.12324
Li Y, Zhang Qok g. A Weibull multi-state model for the dependence of progression-free survival and overall survival. Stat Med. 2015 Jul; 34(17): 2497-2513. doi: 10.1002/sim.6501 Epub 2015 Apr 10. PMID: 25865438
Li Y, Mick R, Heitjan DF. Suspension of accrual in phase II cancer clinical trials. Clinical Trials. 2015 Apr; 12(2): 128-138. doi: 10.1177/1740774514562029 Epub 2015 Jan 7. PMID: 25568092
Li Y, Mick R, Heitjan DF. A Bayesian approach for unplanned sample size in phase II cancer clinical trials. Clinical Trials. 2012 Jul; 9(3): 293-302. doi: 10.1177/1740774512443429. Epub 2012 Apr 20. PMID: 22523304
Li Y, Wileyto EP, Heitjan DF. Prediction of individual long-term outcomes in smoking cessation trials using frailty models. Biometrics. 2011 Dec; 67(4): 1321-1329. doi: 10.1111/j.1541-0420.2011.01578.x. Epub 2011 Mar 14. PMID: 21401566